- Proof-of-concept for in vivo CAR-T generation using non-viral vectors delivering stably integrating DNA
- Durable CAR expression and tumor control in human PBMC engrafted mouse model of B-cell leukemia
WAYNE and UTRECHT – Nov. 8, 2024 — NanoCell Therapeutics, Inc. (“NanoCell”), a company developing a non-viral, DNA-based in vivo gene therapy platform, today announced animal proof of concept data from its lead program utilizing targeted lipid nanoparticle (tLNP) technology for in vivo CAR-T cell generation.
“The studies demonstrated successful targeting and stable CAR expression in a human PBMC engrafted mouse model evaluating the company’s tLNP technology. These findings were initially shared at the 31st Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) in Rome last month. Additional data are being presented at the SITC 39th Annual Meeting in Houston (Abstract #284)]”
These preclinical data demonstrate the potential of our cell-directed, lipid-enabled delivery platform,” said Maurits Geerlings, CEO of NanoCell. “As we progress from platform validation, we are advancing our lead clinical construct, a dual-CAR CD19/CD22 targeting B cell malignancies and autoimmune diseases.”
“Our proof of concept studies demonstrate that our cell-directed, lipid-enabled delivery system can achieve stable CAR expression in T cells in vivo,” said Dr. Jacek Lubelski, Chief Technology Officer of NanoCell. “These results prove the mechanism of action for our non-viral vector technology approach.”
Click here to view Abstract #284
To learn more about our work and stay updated about our latest developments, please visit our website at http://www.nanocelltx.com.
About NanoCell Therapeutics, Inc.
NanoCell Therapeutics is a privately held, transatlantic biotechnology company with locations in Wayne, Pennsylvania, and Utrecht, the Netherlands. We are dedicated to pioneering transformative in-vivo cell engineering through our non-viral, DNA-based gene therapy platform, primarily targeting oncology and autoimmune diseases. NanoCell’s advanced technology platform aims to evolve and enhance traditional adoptive cell therapy methods into advanced in-vivo treatments. Our objective is to streamline the overall treatment process, bolstering patient access, potential clinical benefits, and cost-effective manufacturing. For more information, visit: http://www.nanocelltx.com.
NanoCell Therapeutics Inc. | Investor Relations
T: +31 (0) 70 3643095 | E: contact@nanocelltx.com